Sustained release tablet formulation to treat parkinson disease

Details Sustained release tablet formulation to treat parkinson disease Sustained release tablet formulation to treat parkinson disease

A - Human Necessities

61

K

A61K 31/47 (2006.01) A61K 9/20 (2006.01) A61K 31/4741 (2006.01) A61K 31/4745 (2006.01) A61K 31/495 (2006.01)

Patent

CA 2301869

The sustained release tablet of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5- ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) which is disclosed permits twice daily administration of (R)-5,6-dihydro-5-(methylamino)-4H-imidazo[4,5- ij]-quinolin-2(1H)-one (Z)-2-butenedioate (1:1) to treat humans with Parkinson's disease.

La présente invention concerne un comprimé à dégagement prolongé de (R)-5,6-dihydro-5-(méthylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butènedioate (1:1) permettant l'administration biquotidienne de (R)-5,6-dihydro-5-(méthylamino)-4H-imidazo[4,5-ij]-quinolin-2(1H)-one (Z)-2-butènedioate (1:1) dans le cadre d'un traitement de la maladie de Parkinson chez l'homme.

Affiliated with

Also associated with

Rating

Sustained release tablet formulation to treat parkinson disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sustained release tablet formulation to treat parkinson disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release tablet formulation to treat parkinson disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1380630